What Do Bleeding Gums Have to Do With Alzheimer's Disease?

When my husband sent me an article claiming bleeding gums raise Alzheimer's risk by 61%, the headline sounded alarming. But the science behind it felt familiar.

Years ago, I worked as an investigator on an Alzheimer's trial for a drug targeting Porphyromonas gingivalis, a bacterium linked to severe gum disease. I remember reading the trial packet and being struck by the evidence showing components of this organism in the brains of deceased Alzheimer's patients.

So when this new study dropped, I skipped the hype and went straight to the data.

What the Data Actually Shows

Published in the Journal of Clinical Periodontology in August 2026, the study tracked 1,396 Japanese adults age 60 and older over a decade. None had dementia when the project started. By the end, 267 participants developed dementia—194 of them with Alzheimer's.¹

Dentists performed actual oral exams, measuring pocket depths, tissue loss, and bleeding, rather than relying on self-reported surveys. They even repeated the exams five years later for many participants.

People with the highest rate of bleeding had a 56% higher risk of all-cause dementia and a 61% higher risk of Alzheimer's—the source of the headline. Those with the deepest periodontal pockets had a 72% higher risk of all-cause dementia, while greater clinical attachment loss was associated with a 59% higher risk.

These physical measurements make the findings more compelling than a standard questionnaire, but correlation isn't causation.

The Correlation Trap

Gum health tracks closely with overall health. People with severe gum disease often differ from those without it across several variables, including smoking habits, diabetes rates, diet, income, and access to routine care. Any of these can independently shift dementia risk.

Reverse causation is another hurdle. Alzheimer's changes the brain long before clinical symptoms appear. Subtle cognitive changes could lead to missed dental appointments or neglected brushing years before a diagnosis.

While the researchers used statistical controls to account for many potential confounders, data adjustments only go so far. A strong association isn't proof of cause.

The Bacteria in Question

One important bacterium involved in chronic periodontal disease, P. gingivalis, secretes enzymes called gingipains.

In 2019, a provocative paper in Science Advances reported evidence of P. gingivalis DNA and gingipains in postmortem Alzheimer's brain tissue. Gingipain levels were also associated with Alzheimer's-related pathology, including tau.²

Animal experiments added another piece. Oral P. gingivalis infection resulted in evidence of the organism in the brain, along with increased amyloid-beta, neuroinflammation, and neuronal injury. Blocking gingipains reduced several of those effects.

This pointed to an intriguing possibility: could chronic periodontal infection contribute to the brain changes involved in Alzheimer's?

Note the wording. Contribute, not cause.

Where the Clinical Trial Stumbled

That theory eventually led to the Phase 2/3 GAIN trial, where I served as an investigator. We tested an experimental drug called atuzaginstat (COR388), designed to cross the blood-brain barrier and inhibit P. gingivalis gingipains. Rather than broadly targeting bacteria, the drug targeted a specific mechanism used by P. gingivalis.³

The trial enrolled 643 people with mild-to-moderate Alzheimer's.

The trial failed.

Overall, atuzaginstat did not significantly slow cognitive decline or preserve daily function better than placebo. The drug was also associated with dose-related elevations in liver enzymes.

A prespecified subgroup analysis offered an interesting wrinkle. Among 242 participants with detectable P. gingivalis DNA in their saliva at baseline, the high dose was associated with a reported 57% slowing of cognitive decline on the ADAS-Cog11 compared with placebo. But the benefit wasn't demonstrated on the other co-primary endpoint measuring daily function.

A subgroup finding within an otherwise negative trial does not establish that the drug worked. But it left researchers with an interesting question: if P. gingivalis contributes to Alzheimer's disease in only some people, would a treatment targeting it be expected to work in everyone?

Why Alzheimer's Resists Single Solutions

The trial's outcome also illustrates a larger problem in Alzheimer's research. People who look similar clinically can have very different mixtures of pathology underneath—amyloid, tau, vascular disease, genetics, metabolic dysfunction, inflammation, and potentially other contributors we don't fully understand yet.

Gum disease could fit somewhere within that larger picture. Researchers are studying several possible connections, including chronic systemic inflammation, vascular effects, disruption of the blood-brain barrier, and exposure to periodontal bacteria or bacterial products.

None of those mechanisms has established P. gingivalis as a cause of Alzheimer's disease.

But the relationship between oral health and brain health remains worth studying.

What This Means for You

A relative risk increase of 61% doesn't mean you have a 61% chance of getting Alzheimer's if your gums bleed. Nor does it mean that flossing has been proven to protect your brain.

Gum disease is worth treating on its own merits. Brush, floss, and see a dentist if your gums bleed—just do it for your mouth, not because an online headline promised it would ward off memory loss.

Years after working on a trial built around one version of this hypothesis, seeing new studies come out feels like a full-circle moment. We don't have definitive answers yet, but it remains a path worth exploring.

References

1. Furuta M, Ohara T, Sakata S, et al. Periodontal status and the risk of all-cause dementia, Alzheimer's disease and vascular dementia in a community: the Hisayama Study. J Clin Periodontol. Published online August 16, 2026. doi:10.1111/jcpe.70185
2. Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333. doi:10.1126/sciadv.aau3333
3. ClinicalTrials.gov. GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease. NCT03823404. https://clinicaltrials.gov/study/NCT03823404